ZA200301818B - Novel piperidine derivatives. - Google Patents

Novel piperidine derivatives. Download PDF

Info

Publication number
ZA200301818B
ZA200301818B ZA200301818A ZA200301818A ZA200301818B ZA 200301818 B ZA200301818 B ZA 200301818B ZA 200301818 A ZA200301818 A ZA 200301818A ZA 200301818 A ZA200301818 A ZA 200301818A ZA 200301818 B ZA200301818 B ZA 200301818B
Authority
ZA
South Africa
Prior art keywords
methyl
amino
phenyl
alkyl
compounds according
Prior art date
Application number
ZA200301818A
Other languages
English (en)
Inventor
Jean Ackermann
Alexander Chucholowski
Olivier Morand
Thomas Weller
Johannes Aebi
Henrietta Dehmlow
Sabine Wallabaum
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200301818B publication Critical patent/ZA200301818B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200301818A 2000-09-08 2003-03-05 Novel piperidine derivatives. ZA200301818B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00119677 2000-09-08

Publications (1)

Publication Number Publication Date
ZA200301818B true ZA200301818B (en) 2004-06-21

Family

ID=8169794

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301818A ZA200301818B (en) 2000-09-08 2003-03-05 Novel piperidine derivatives.

Country Status (15)

Country Link
US (1) US6964974B2 (de)
EP (1) EP1317432B1 (de)
JP (1) JP2004508354A (de)
KR (1) KR20030027122A (de)
CN (1) CN1231466C (de)
AR (1) AR032634A1 (de)
AT (1) ATE384047T1 (de)
AU (1) AU2001285912A1 (de)
BR (1) BR0113752A (de)
CA (1) CA2419588C (de)
DE (1) DE60132468T2 (de)
ES (1) ES2298253T3 (de)
MX (1) MXPA03002034A (de)
WO (1) WO2002020483A1 (de)
ZA (1) ZA200301818B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030086A2 (en) 2000-08-16 2005-02-28 F. Hoffmann - La Roche Ag Novel aminocyclohexane derivatives
BR0214967A (pt) 2001-12-14 2005-05-10 Novo Nordisk As Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
CA2589748C (en) * 2004-12-24 2013-08-13 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
EP2658544A4 (de) * 2010-12-27 2014-05-28 Univ Missouri Oxidosqualenzyklase als proteintarget für antikrebs-therapeutika
AU2012321107A1 (en) * 2011-10-20 2013-05-16 The Curators Of The University Of Missouri Enzyme inhibitor for cancer treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3914426A (en) * 1972-11-10 1975-10-21 Pfizer Piperidinesulfonylurea derivatives for lowering blood sugar levels
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
FR2705343B1 (fr) 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
GB9310066D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
DE4407961A1 (de) 1994-03-10 1995-09-14 Thomae Gmbh Dr K Imidazolidin-2-one, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19618970A1 (de) 1996-05-10 1997-11-13 Klinge Co Chem Pharm Fab Neue Thiazolopyridine
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU747531B2 (en) * 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
DE19806713A1 (de) 1998-02-18 1999-08-19 Boehringer Ingelheim Pharma Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
WO2002020483A1 (en) 2002-03-14
CN1468220A (zh) 2004-01-14
CA2419588C (en) 2009-09-22
DE60132468D1 (de) 2008-03-06
CN1231466C (zh) 2005-12-14
JP2004508354A (ja) 2004-03-18
WO2002020483A8 (en) 2002-06-06
ATE384047T1 (de) 2008-02-15
US20020068753A1 (en) 2002-06-06
MXPA03002034A (es) 2003-07-24
EP1317432A1 (de) 2003-06-11
KR20030027122A (ko) 2003-04-03
ES2298253T3 (es) 2008-05-16
EP1317432B1 (de) 2008-01-16
AU2001285912A1 (en) 2002-03-22
BR0113752A (pt) 2003-07-29
CA2419588A1 (en) 2002-03-14
US6964974B2 (en) 2005-11-15
DE60132468T2 (de) 2009-01-15
AR032634A1 (es) 2003-11-19

Similar Documents

Publication Publication Date Title
US4810713A (en) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
JP4486817B2 (ja) 1,4−ジヒドロ−1,4−ジフェニルピリジン誘導体
US20060211717A1 (en) Quinoline and quinazoline derivatives and drugs containing the same
EP1626716B1 (de) Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung
MXPA06014573A (es) Compuestos amido y su uso como farmaceuticos.
US3962449A (en) Cardioactive bispidones and bispidines
CZ291294B6 (cs) Nové heterocyklické sloučeniny
EP2582670A1 (de) Piperidinylverbindungen als modulator der chemokin-rezeptoraktivität
PT98437A (pt) Processo para a preparacao de novos piperidil-eteres e tioeteres e de composicoes farmaceuticas que os contem
ZA200304646B (en) Dihydroindole and tetrahydroquinoline derivatives.
US4650874A (en) N-(aralkoxybenzyl)-4(benzhydryl) piperidines
ZA200302742B (en) Cholesterol lowering benzo(b) thiophenes and benzo(d) isothiazoles.
ZA200300164B (en) Novel aniline derivatives.
EP1317432B1 (de) Piperidin-derivate zur verwendung als 2,3-oxidosqualen-lanosterol zyklase inhibitoren
US5350758A (en) Piperidyl sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
KR100287575B1 (ko) 알파,오메가 - 디아릴알칸 유도체, 그의 제조방법, 및 순환계 질환 및 정신병의 치료 및 예방용 용도
DE60216967T2 (de) Substituierte cyclohexanderivate
ZA200300900B (en) Novel aminocyclohexane derivatives.
KR20110128193A (ko) 의약제로서의 아토르바스타틴 락톨의 용도
FI106551B (fi) Menetelmä lääkeaineena käyttökelpoisen alfa-[(heterosyklyylialkoksi)fenyyli]-omega-aryylialkaani- tai alfa-((heterosyklyylioksi)fenyyli)-omega-aryylialkaaniyhdisteen valmistamiseksi
HK1090295B (en) Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity
HK1010831A (en) Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis
HK1011984A (en) Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis
JPH10182596A (ja) 脂質代謝改善剤